Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
T
TTX
vs
S
S&P/ASX 300
Over the past 12 months, TTX has significantly outperformed S&P/ASX 300, delivering a return of +64% compared to S&P/ASX 300's 3% drop.
Stocks Performance
TTX vs S&P/ASX 300
Performance Gap
TTX vs S&P/ASX 300
Performance By Year
TTX vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Tetratherix Ltd
Glance View
Tetratherix is a medical technology company built around injectable biomaterial products that can be placed into the body and then form a temporary scaffold. The idea is to help surgeons and clinicians fill spaces, support healing, and deliver cells or drugs at the site that needs treatment. Its core work sits in regenerative medicine, where the company’s materials are meant to support tissue repair rather than act as a permanent implant. The company makes money by selling its biomaterial products to hospitals, doctors, and other healthcare partners, and by working with industry partners that want to use its materials in their own procedures or treatments. In this kind of business, success depends on developing products that are easy to use in the clinic, compatible with medical workflows, and suitable for specific surgical or therapeutic applications. What makes Tetratherix different is that it is not a broad device maker or a drug company. It focuses on a specific layer of the healthcare chain: the material that goes into the patient first and helps create the conditions for healing. That gives it a niche role in regenerative medicine, where the product has to work both as a physical scaffold and as a platform for other therapies.